Literature DB >> 26021967

MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder.

Maria Gabriela Nielsen1, Chiara Congiu2, Marco Bortolomasi3, Cristian Bonvicini4, Stefano Bignotti5, Maria Abate3, Elena Milanesi6, Andreas Conca7, Nadia Cattane2, Elisabetta Tessari3, Massimo Gennarelli8, Alessandra Minelli9.   

Abstract

BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) genetic variations have been widely studied in major depressive disorder (MDD) and antidepressants outcome. An interaction with catechol-O-methyltransferase (COMT) has also been proved affecting depression. The aim of this study was to clarify the role of the most commonly studied single nucleotide polymorphisms (SNPs) of MTHFR gene in MDD and in treatment response mechanisms, along with the impact of the interaction with COMT.
METHODS: A total of 613 MDD patients, of whom 389 were classified as having treatment resistant depression (TRD), and 463 controls were enrolled. The A1298C, C677T and COMT Val158Met were genotyped. Genetic data were integrated with a transcriptional level analysis in peripheral blood cells (PBCs) and fibroblasts.
RESULTS: The A1298C CC homozygotes were more frequent in MDD patients compared to controls in women, increasing twice the genetic risk to develop depression. Moreover this genotype resulted in epistasis with COMT Met carriers in association with MDD. No significant effects were obtained concerning response to treatment. Transcriptional analyses highlighted a strong correlation between the mRNA levels of MTHFR in fibroblasts and COMT genotypes whereas no significant association with MDD was found. PBCs results revealed relevant influences of environmental factors. LIMITATION: We did not measure folate and homocisteine levels.
CONCLUSION: This study showed the involvement of A1298C, Val158Met and their interaction in MDD. The transcriptional analyses supported the participation of COMT in the folate pathway, which partakes in the complex network of gene×gene and gene×environment interactions of MDD etiopathogenesis.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Catechol-O-methyltransferase; Fibroblasts; Major depressive disorder; Methylenetetrahydrofolate reductase; Transcriptional analyses; Treatment resistant depression

Mesh:

Substances:

Year:  2015        PMID: 26021967     DOI: 10.1016/j.jad.2015.05.003

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

Review 1.  A Systematic Review of Candidate Genes for Major Depression.

Authors:  Audrone Norkeviciene; Romena Gocentiene; Agne Sestokaite; Rasa Sabaliauskaite; Daiva Dabkeviciene; Sonata Jarmalaite; Giedre Bulotiene
Journal:  Medicina (Kaunas)       Date:  2022-02-14       Impact factor: 2.430

2.  Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder.

Authors:  A Minelli; C Magri; A Barbon; C Bonvicini; M Segala; C Congiu; S Bignotti; E Milanesi; L Trabucchi; N Cattane; M Bortolomasi; M Gennarelli
Journal:  Transl Psychiatry       Date:  2015-12-01       Impact factor: 6.222

Review 3.  Methylenetetrahydrofolate Reductase A1298C Polymorphism and Major Depressive Disorder.

Authors:  Kevin Cho; Zubair M Amin; Jie An; Kerry Anne Rambaran; Tyler B Johnson; Saeed K Alzghari
Journal:  Cureus       Date:  2017-10-01

4.  Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response.

Authors:  Pierre Mesdom; Romain Colle; Elise Lebigot; Séverine Trabado; Eric Deflesselle; Bruno Fève; Laurent Becquemont; Emmanuelle Corruble; Céline Verstuyft
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

5.  Roles of 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in early- and late-onset obsessive-compulsive disorder.

Authors:  Metin Caliskan; Seda Orenay-Boyacioglu; Ayse Dondu
Journal:  Indian J Psychiatry       Date:  2019 Mar-Apr       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.